SG

Swapna Gorantla

Active Director Director DIN 06750818
DIN 06750818 First appointment Dec 2013 Primary industry Pharma
Unlock full profile Investments · shareholding · contact details
Current companies 1 active board seats
Total affiliations 1 Since Dec 2013
Shareholding value •••• Premium profile

About Swapna Gorantla

Data last updated:

Swapna Gorantla is a Director at Arkas Pharma Private Limited (since 2013). The company operates in Pharma. Arkas Pharma Private Limited reported revenue of ₹12.05 Cr (FY 2024).

DIN 06750818
Primary Designation Director
Industry Pharma
First Appointment 12 Dec 2013
Oldest Company Age 12 yrs
Largest company Arkas Pharma Private Limited · ₹12.05 Cr (FY 2024)

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Arkas Pharma Private Limited U24232TG2013PTC091634
Director12 Dec 20132013₹12.05 Cr (FY 2024)Active

Board colleagues of Swapna Gorantla

Directorship timeline

Open interactive timeline →
Arkas Pharma Private Limited
Premium access

Shareholding and investment profile for Swapna Gorantla

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Swapna Gorantla

Swapna Gorantla currently holds 1 directorship: Arkas Pharma Private Limited (Director, since 12 Dec 2013, revenue ₹12.05 Cr (FY 2024)).

Swapna Gorantla was first appointed on 12 Dec 2013 as Director at Arkas Pharma Private Limited.

The current boards of Swapna Gorantla's companies include Anil Kumar Gorantla (Arkas Pharma Private Limited), Raja Shekar (Arkas Pharma Private Limited).

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available